The reality of invasive strategies in non-ST-elevation acute coronary syndrome;La realidad de la estrategia invasiva en el síndrome coronario agudo sin elevación del segmento ST

Revista Espanola de Cardiologia

Volumn 57, Issue 12, 2004, Pages 1133-1135

  Gómez Hospital, Joan Antoni ^a   Cequier, Ángel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST;

BLOOD CLOT LYSIS; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CORONARY ARTERY BYPASS GRAFT; EDITORIAL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MORTALITY; PROGNOSIS; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 12544255799     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13069857     Document Type: Editorial

References (11)

1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2002;40: 1366-74.
2. López Bescos L, Arós F, Lidón RM, Cequier A, Bueno H, Alonso JJ, et al. Actualización (2002) de las guías de práctica clínica de la Sociedad Española de Cardiología en angina inestable/infarto sin elevación del segmento ST. Rev Esp Cardiol 2002;55:631-42.
3. Anderson HV, Cannon CP, Stone PH, Williams DO, Mccabe CH, Knatterud GL, et al. One-year results of the thrombolysis in myocardial infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995;26:1643-50.
4. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, et al. Outcomes in patients with acute non-Q wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998;338:1785-92.
5. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary artery disease: the FRISC II invasive randomised trial. Lancet 2000;356:9-16.
6. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
7. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002;360:743-51.
8. Bodí V, Sanchis J, Llácer A, Fàcila L, Núñez J, Pellicer M, et al. Estrategia invasiva en el síndrome coronario agudo sin elevación del segmento ST. De los grandes estudios al mundo real. Rev Esp Cardiol 2004;57:1143-50.
9. Bosch X, Verbal F, Lopez de Sa E, Miranda-Guardiola F, Borquez E, Bethencourt A, et al. Diferencias en el tratamiento y en la evolución clínica de los pacientes con síndrome coronario agudo sin elevación del segmento ST en función del servicio clínico de ingreso. Rev Esp Cardiol 2004;57:283-90.
10. Permanyer Miralda G, Brotons C, Moral I, Ribera A, Calvo F, Campreciós M, et al. Pacientes con síndrome coronario agudo: abordaje terapéutico (patrones de manejo) y pronó stico al año en un hospital general terciario. Rev Esp Cardiol 1998; 51:954-64.
11. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J 2002;23:1441-8.